The positive rate of persistent CTCs (36.2%, 51 out of 141) is parallel to the rate of abnormal elevated serum CEA (33.3%, 47 out of 141) in our postoperative stages II–III colon cancer patients. This evidence concerns the gene CEACAM5 and malignant colon neoplasm.